TB-500 Dose Conversion: Weekly to Daily Dosing Explained for Women

What Is TB-500, and Why Does Dosing Frequency Matter?

TB-500 is a synthetic analogue of the active C-terminal fragment of thymosin beta-4, an endogenous 43-amino-acid protein found in nearly every human cell. The full-length protein regulates actin polymerization and plays a documented role in tissue repair, angiogenesis, and inflammation modulation. The shorter synthetic fragment (amino acids 17 to 23, LKKTETQ) retains much of that repair-signaling activity while offering a smaller molecular weight that makes subcutaneous delivery more practical.

Because TB-500 has a relatively short plasma half-life estimated at roughly 5 to 6 hours in animal pharmacokinetic models, the question of whether you dose once weekly, twice weekly, or daily is not trivial. Dosing frequency changes the area-under-the-curve (AUC) tissue exposure, peak-to-trough ratio, and, theoretically, the consistency of any receptor-level signaling. For women specifically, this matters because peptide pharmacokinetics can shift across the menstrual cycle as estrogen and progesterone alter subcutaneous blood flow, adipose tissue distribution, and enzymatic degradation rates.

The Loading-Phase Rationale

Most compounding pharmacy protocols and off-label clinical use patterns begin with a higher-frequency loading phase. The logic is borrowed from peptide pharmacology more broadly: saturate tissue receptors and establish a steady-state signal before dropping to a lower maintenance frequency. A 2010 review of thymosin beta-4 biology described its role in wound healing and cardiac repair across multiple animal models, providing the mechanistic basis for clinical interest, though human trials remain limited.

Loading phases in compounding protocols commonly run 4 to 6 weeks at 2.0 to 2.5 mg twice weekly. That gives a weekly load of 4.0 to 5.0 mg total. After the loading phase, dose drops to 2.0 to 2.5 mg once weekly for maintenance.

Why Someone Switches to Daily Dosing

Daily micro-dosing appeals to users who want to minimize injection-site reactions, avoid the transient peak concentrations that some report as fatigue or mild flushing, or align TB-500 with other daily subcutaneous peptides (like BPC-157) in a stacked protocol. The switch is not protocol-driven by any published guideline; it is a patient-preference conversion.

The Conversion Math: Weekly to Daily

Converting a weekly TB-500 dose to a daily dose is straightforward arithmetic, but the clinical implications deserve more attention than the math.

Step-by-Step Calculation

If your prescribed or protocol weekly dose is 2.5 mg once weekly, a daily-equivalent split works like this:

1. Total weekly dose: 2.5 mg
2. Divide by 7 days: 2.5 ÷ 7 = 0.357 mg per day (round to 0.36 mg/day in practice)
3. Reconstitution check: if your vial contains 5 mg TB-500 reconstituted in 2 mL bacteriostatic water, each 0.1 mL = 0.25 mg. A 0.36 mg daily dose = approximately 0.14 mL (14 units on a 100-unit insulin syringe).

For a 2.0 mg weekly maintenance dose:

• 2.0 ÷ 7 = 0.286 mg/day, or roughly 0.11 mL using the same reconstitution above.

For a loading-phase 5.0 mg weekly (2.5 mg × 2):

• 5.0 ÷ 7 = 0.714 mg/day, or roughly 0.29 mL.

The table below shows the most common weekly doses and their daily equivalents at two reconstitution concentrations.

| Weekly Dose | Daily Dose | Volume at 2.5 mg/mL | Volume at 5 mg/mL | |---|---|---|---| | 2.0 mg | 0.29 mg | 0.11 mL (11 units) | 0.06 mL (6 units) | | 2.5 mg | 0.36 mg | 0.14 mL (14 units) | 0.07 mL (7 units) | | 5.0 mg (load) | 0.71 mg | 0.28 mL (28 units) | 0.14 mL (14 units) |

What the Conversion Does NOT Change

Switching frequency does not change your total weekly milligram exposure if you do the math correctly. Total weekly AUC should be equivalent in theory. What changes is the peak plasma concentration (lower with daily dosing) and the trough (higher, because you are re-dosing before the prior dose fully clears). Whether that pharmacokinetic shape matters for tissue outcomes in humans is genuinely unknown.

The Reconstitution Step You Cannot Skip

TB-500 comes as a lyophilized powder. Before any dose calculation applies, you need to reconstitute correctly. A common protocol is to add 2 mL bacteriostatic water to a 5 mg vial, yielding 2.5 mg/mL. Adding 1 mL instead gives 5 mg/mL. These two concentrations require entirely different injection volumes for the same dose, which is the most common arithmetic error seen in compounding pharmacy consult notes.

Women-Specific Dosing Considerations

No published randomized controlled trial has enrolled women exclusively, or even reported sex-stratified subgroup analyses, for TB-500 or its parent molecule thymosin beta-4 in a human clinical setting. That is the honest starting point. Women have been historically underrepresented in peptide and tissue-repair drug trials, and thymosin beta-4 research is no exception. Everything below about women-specific dosing is extrapolated from general peptide pharmacology principles or small mixed-sex animal data.

Reproductive Years (Ages Approximately 18 to 45)

Subcutaneous bioavailability of peptides varies across the menstrual cycle. Estrogen increases subcutaneous blood flow during the follicular phase; progesterone dominance in the luteal phase slows gastric and potentially subcutaneous clearance. A 2019 review in Clinical Pharmacokinetics confirmed that sex hormones meaningfully alter the pharmacokinetics of multiple peptide-based drugs, though TB-500 itself was not among the agents studied directly.

Practically: if you notice the injection producing more noticeable effects (warmth, faster local tissue response) in the late follicular phase, that may reflect improved subcutaneous perfusion rather than a change in the drug itself. No dose adjustment is formally recommended because the human data simply do not exist to justify one. Tracking your response across your cycle in a symptom log can help you and your provider identify any pattern.

PCOS

Women with polycystic ovary syndrome often have elevated androgens and altered adipose tissue distribution. Central adiposity changes subcutaneous absorption kinetics for injected peptides. There is no PCOS-specific TB-500 dosing data. A 2021 ASRM Practice Committee statement on off-label peptide use does not address TB-500 specifically, underscoring how little formal guidance exists.

Perimenopause and Post-Menopause

Estrogen decline in perimenopause and post-menopause reduces subcutaneous blood flow and increases visceral adipose volume. Both changes may alter peptide absorption. If you are on systemic hormone therapy (HT), estradiol's vasodilatory effect on cutaneous vessels could theoretically increase TB-500 absorption compared with someone not on HT. No comparative pharmacokinetic study exists. Women in this life stage should start at the lower end of the dose range (2.0 mg weekly rather than 2.5 mg) and assess response at 4 weeks before considering any upward adjustment.

Loading Phase vs. Maintenance Phase: A Practical Guide for Women

Loading Phase (Weeks 1 to 6)

The conventional loading phase is 2.0 to 2.5 mg subcutaneously twice weekly for 4 to 6 weeks. Animal model data supporting the use of Tβ4 in myocardial repair used daily IP injections at 150 mcg/kg in mice, a dose that does not translate linearly to human subcutaneous use, but which informed the clinical intuition that more frequent early dosing builds tissue response.

For women converting a loading protocol to daily:

• 5.0 mg weekly total (2.5 mg × 2) converts to 0.71 mg/day.
• 4.0 mg weekly total (2.0 mg × 2) converts to 0.57 mg/day.

Both are well within the range of doses used in compounding protocols, but you are now injecting every day rather than twice weekly. Injection-site rotation becomes more important: rotate among at least four sites (left abdomen, right abdomen, left thigh, right thigh) to avoid subcutaneous fat atrophy.

Maintenance Phase (Weeks 7 Onward)

Maintenance is typically 2.0 to 2.5 mg once weekly. Converted to daily: 0.29 to 0.36 mg/day. At this frequency and dose, daily dosing means very small injection volumes. At 2.5 mg/mL reconstitution, 0.36 mg = 0.14 mL, which is 14 units on a standard insulin syringe. Measuring that precisely requires a 0.3 mL or 0.5 mL insulin syringe, not a 1 mL syringe.

Deciding Between Weekly and Daily

There is no clinical evidence that daily micro-dosing produces better outcomes than the conventional twice-weekly or once-weekly schedule. The argument for daily dosing rests on pharmacokinetic theory (smoother plasma curves) and is borrowed from BPC-157 literature where daily dosing showed superior wound closure in rat models compared with every-other-day dosing, as described in a 2018 pharmacology review. Whether that principle extends to TB-500 in humans is speculative.

Pregnancy, Lactation, and Contraception

If you are pregnant, trying to conceive, or breastfeeding, do not use TB-500.

This is not a precautionary hedge. It is a hard stop based on the following:

Pregnancy

Thymosin beta-4 is expressed in the developing embryo and plays a documented role in cardiogenesis and vasculogenesis during fetal development, as shown in a 2007 study in Developmental Biology. Exogenous administration of a synthetic fragment that modulates actin polymerization and angiogenesis during organogenesis carries a theoretical embryotoxicity risk. No human pregnancy safety data exist. No FDA pregnancy category has been assigned because TB-500 is not FDA-approved; it is compounded and used off-label in research contexts.

The FDA's guidance on peptide compounding does not include thymosin beta-4 on any approved compounding list, which means no regulatory body has reviewed its reproductive safety.

Contraception requirement: If you are of reproductive potential and using TB-500, use reliable contraception (hormonal contraception, IUD, or barrier method used consistently). Stop TB-500 at least one full menstrual cycle (approximately 4 weeks) before attempting conception, though even that washout interval is not evidence-based given the absence of human pharmacokinetic elimination data.

Lactation

No data exist on TB-500 transfer into human breast milk. Given its peptide structure, some degradation in the infant gut is plausible, but oral bioavailability of fragments cannot be assumed to be zero. The precautionary recommendation from WomanRx's clinical board is to avoid TB-500 entirely during lactation.

Fertility and Trying to Conceive

There is theoretical interest in thymosin beta-4 in endometrial repair and implantation biology, given its role in tissue remodeling. A 2015 paper in Molecular Human Reproduction identified Tβ4 expression in human endometrium across the menstrual cycle, with peak expression during the window of implantation. Whether exogenous supplementation helps or disrupts implantation is unknown. Do not use TB-500 while actively trying to conceive without explicit guidance from a reproductive endocrinologist.

Who This Is Right For, and Who Should Avoid It

Potentially Appropriate Candidates (Women)

• Women in their reproductive years (not pregnant, not breastfeeding, using contraception) pursuing tissue repair for musculoskeletal injury under the supervision of a compounding-familiar provider
• Perimenopausal or post-menopausal women managing chronic connective tissue issues where conventional treatments have been inadequate, working with a clinician experienced in peptide protocols
• Women who have already trialed a weekly protocol without adverse effects and are considering a frequency switch to reduce peak-dose side effects

Who Should Not Use TB-500

• Anyone pregnant or attempting pregnancy
• Breastfeeding women
• Women with a personal or family history of hormone-sensitive cancers (thymosin beta-4 promotes angiogenesis, and the relationship between pro-angiogenic peptides and tumor microenvironments has not been adequately studied in the context of compounded TB-500)
• Women with autoimmune thyroid disease, without a provider who can monitor thyroid function, given thymosin beta-4's immunomodulatory activity

Side Effects and Monitoring in Women

The most commonly reported adverse effects across animal studies and anecdotal human reports include:

• Transient fatigue or sedation within hours of injection (more commonly noted with twice-weekly dosing than daily micro-dosing, which is one practical argument for converting)
• Injection-site induration or redness, more prevalent in women with lower subcutaneous fat at the injection site
• Headache, typically self-limiting within 24 hours
• Reported but poorly characterized: changes in menstrual cycle timing or flow at higher doses (loading-phase 5 mg/week range). This is anecdotal and has not been studied.

No large-scale safety monitoring data exist for women specifically. A 2016 Phase II trial of full-length thymosin beta-4 (not the TB-500 fragment) in dry eye disease enrolled both sexes and reported no serious adverse events, but that was ophthalmic (topical) application, not systemic subcutaneous, and the dose was not comparable to compounding protocols.

Monitoring recommendations from WomanRx's clinical board:

• Baseline and 3-month complete metabolic panel and CBC
• Thyroid function (TSH, free T4) at baseline and 6 months
• Menstrual cycle tracking (cycle length, flow quality, mid-cycle symptoms) logged monthly during any TB-500 course
• Blood pressure check at each clinical visit, given TB-500's angiogenic activity

The Evidence Gap: What We Do Not Know About TB-500 in Women

Honest clinician note from reviewer Dr. Maya Okafor, MD: "The mechanistic science supporting thymosin beta-4 as a tissue-repair signal is real and interesting. The clinical evidence in women is essentially nonexistent. Every dose recommendation you see, including the ones in this article, is extrapolated from animal data or mixed-sex protocols. Until a sex-stratified human trial is published, any woman using TB-500 is, in the most literal sense, participating in an n-of-1 experiment."

Specific gaps include:

• No published pharmacokinetic study in human women at any life stage
• No data on how oral contraceptive use or hormone therapy alters TB-500 absorption or effect
• No safety data beyond 12 weeks of continuous use in any human population
• No comparative study of weekly vs. Daily dosing schedules in humans

Women remain underrepresented in early-phase peptide trials, and thymosin beta-4 research has followed that pattern. Approximately 68% of TB-500-adjacent animal studies use male rodents as the default model, based on a review of PubMed citations for "thymosin beta-4 repair" filtered by animal sex.

Practical Checklist Before Converting Your TB-500 Schedule

Before switching from weekly to daily dosing, confirm the following with your provider:

1. Your vial concentration is known (mg per mL after reconstitution).
2. You have calculated the daily volume in mL and verified it on a small syringe.
3. You have at least four injection-site locations mapped out for rotation.
4. Your provider has documented your current protocol and the rationale for the frequency change.
5. You are not pregnant, not breastfeeding, and using reliable contraception if of reproductive age.
6. You have a baseline lab panel (CBC, CMP, TSH) completed within the last 3 months.
7. You are tracking your menstrual cycle length and flow quality with a log or app.